DISE-CAD: Mechanisms of Upper Airway Obstruction

Sponsor
University of Pennsylvania (Other)
Overall Status
Recruiting
CT.gov ID
NCT04322097
Collaborator
(none)
100
1
1
57.9
1.7

Study Details

Study Description

Brief Summary

The current study is designed to examine underlying mechanisms of action of lingual muscles in the maintenance of airway patency during sleep. The investigators' major hypothesis is that specific tongue muscles are responsible for relieving upper airway obstruction during sleep.

Condition or Disease Intervention/Treatment Phase
  • Device: Lingual Muscle Stimulation
  • Diagnostic Test: Mandibular advancement
  • Device: Postural maneuvers
N/A

Detailed Description

Obstructive sleep apnea (OSA) is characterized by recurrent upper airway obstruction due to inadequate muscle tone during sleep leading to nocturnal hypercapnia, repeated oxyhemoglobin desaturations and arousals. Continuous positive airway pressure (CPAP) is the therapeutic mainstay for OSA, but adherence remains poor. The loss of motor input to the tongue during sleep has been implicated as a cause for upper airway collapse. Activation of tongue muscles with implanted hypoglossal nerve stimulators is an effective therapy for some OSA patients. Nevertheless, approximately 1/3 of OSA patients did not respond to hypoglossal nerve stimulation despite rigorous selection criteria, leaving large segments of CPAP intolerant patients at risk for OSA-related morbidity. Thus, there is a critical knowledge gap in the role of lingual muscle activity in the maintenance of airway patency.

The current study is designed to examine underlying mechanisms of action of lingual muscles in the maintenance of airway patency during sleep. The investigators' major hypothesis is that specific tongue muscles are responsible for relieving upper airway obstruction during sleep. To address this hypothesis, the investigators will (1) selectively stimulate specific lingual muscle groups (viz., protrudors and retractors) and measure effects on airway patency during Drug Induced Sleep Endoscopy (DISE). The investigators will also (2) correlate responses in patency to alterations in tongue morphology (as assessed with ultrasound imaging). A final goal is to (3) examine the impact of anatomic factors (e.g., the size of the maxillo-mandibular enclosure) on airway responses to stimulation.

Objectives (all primary and secondary objectives)

  1. To assess effects of stimulating specific lingual muscles on upper airway patency during DISE and on tongue morphology.

The investigators hypothesize that stimulation will lead to improvements in upper airway patency during DISE when tongue protrudors are stimulated, and that concomitant stimulation of retractors will augment this response.

  1. To correlate improvements in upper airway patency during sleep with stimulation to alterations in tongue shape and position when stimulating during DISE.

The investigators hypothesize that the restoration of airway patency during sleep will be associated with anterior tongue movement and preservation of tongue shape when stimulated during DISE.

  1. To assess whether craniofacial morphology predicts improvements in pharyngeal patency during DISE with stimulation.

The investigators hypothesize that maxillo-mandibular restriction will be associated with diminished responses in airway patency to stimulation during DISE.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Characterizing Mechanisms of Upper Airway Obstruction During Drug-Induced Sleep Endoscopy (DISE)
Actual Study Start Date :
Jun 3, 2020
Anticipated Primary Completion Date :
Apr 1, 2025
Anticipated Study Completion Date :
Apr 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Other: DISE patients

DISE

Device: Lingual Muscle Stimulation
Tongue protrudor and retractor muscles will be stimulated separately and in combination

Diagnostic Test: Mandibular advancement
Outcome variables will be assess with and without mandibular advancement

Device: Postural maneuvers
Outcome variables will be measured with and without postural maneuvers

Outcome Measures

Primary Outcome Measures

  1. Upper airway critical pressure (Pcrit) [Within 3 months of enrollment]

    Measurement of airway collapsibility (cmH2O)

  2. Pharyngeal compliance [Within 3 months of enrollment]

    area/pressure in cm2 per cmH2O

  3. Amax [Within 3 months of enrollment]

    Measurement of maximal pharyngeal cross-sectional area (in cm-squared)

  4. Segmental Airway Resistances [Within 3 months of enrollment]

    Measurement of pharyngeal resistances upstream and downstream to site of collapse (cmH2O/l/s)

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adults (≥ 22yrs)

  • Moderate to severe obstructive sleep apnea (AHI ≥ 20)

  • No underlying cardiac disease

Exclusion Criteria:
  • Significant cardiac disease, unstable or recent cardiac events

  • Active pulmonary, liver, or renal disease

  • Uncontrolled hypertension (BP>160/100)

  • Neuromuscular disease

  • Major psychiatric disease

  • Lifestyle considerations by the use of excessive alcohol, tobacco, or drugs and involvement in shift work occupations that preclude study in the laboratory

  • Pregnancy

  • Anticoagulation therapy (e.g. Coumadin, Dabigatran)

  • MRI contraindications (claustrophobia, ferromagnetic implants/foreign bodies, etc.)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital of the University of Pennsylvania Philadelphia Pennsylvania United States 19104

Sponsors and Collaborators

  • University of Pennsylvania

Investigators

  • Principal Investigator: Raj C Dedhia, MD, University of Pennsylvania

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Raj Dedhia, MD, Associate Professor, Director, Division of Sleep Surgery, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT04322097
Other Study ID Numbers:
  • 833511
First Posted:
Mar 26, 2020
Last Update Posted:
Nov 24, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Raj Dedhia, MD, Associate Professor, Director, Division of Sleep Surgery, University of Pennsylvania
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 24, 2021